Drug intelligence / Profile preview

UMD#3

Development stage: Preclinical
Lead developer: Avadel Pharmaceuticals

Overview

UMD#3 is a placeholder name for an unnamed pharmaceutical product that was under FDA review. It was part of the portfolio acquired by Flamel Technologies from Éclat Pharmaceuticals, LLC, as a key component of Flamel's strategy to build an Unapproved Marketed Drugs (UMDs) business.

Beyond the preview

Go deeper on UMD#3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UMD#3.

Explore the full profile